<p>Artivion, Inc.（纽约证券交易所代码：AORT - 获取免费报告）的股票在目前覆盖该股票的九家券商中获得了 “适度买入” 的共识推荐，Marketbeat 报道称。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，七位给予了买入评级。在过去一年中更新了对该股票覆盖的券商中，平均一年目标价为 49.1143 美元。</p>
<p>AORT 已成为多份研究分析师报告的主题。华尔街禅在 12 月 21 日的研究报告中将 Artivion 的股票评级从 “买入” 上调至 “强力买入”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Artivion 股票的 “卖出（d-）” 评级。Needham &amp; Company LLC 在 11 月 7 日的报告中将 Artivion 的目标价从 50.00 美元上调至 58.00 美元，并给予该股票 “买入” 评级。Canaccord Genuity Group 在 12 月 17 日的研究报告中重新发布了 “买入” 评级，并对 Artivion 股票设定了 51.00 美元的目标价。最后，JMP Securities 在 10 月 10 日的研究报告中将 Artivion 的目标价从 42.00 美元上调至 47.00 美元，并给予该股票 “市场表现优于大盘” 评级。</p>
<p><strong>阅读我们关于 Artivion 的最新研究报告</strong></p>
<h2>Artivion 的内部买卖</h2>
<p>在其他新闻中，首席执行官 James P. Mackin 于 11 月 13 日星期四出售了 34,210 股公司的股票。股票以平均价格 45.86 美元出售，总价值为 1,568,870.60 美元。交易后，首席执行官持有 800,993 股公司股票，估值约为 36,733,538.98 美元。此交易代表其持股比例下降了 4.10%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，副总裁 Marshall S. Stanton 于 11 月 21 日星期五出售了 47,376 股公司的股票。该股票以平均价格 45.04 美元出售，总交易额为 2,133,815.04 美元。出售后，副总裁直接持有 44,753 股公司的股票，估值约为 2,015,675.12 美元。此交易代表其持股比例下降了 51.42%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 234,511 股公司股票，价值 10,612,452 美元。公司内部人士目前持有 8.10% 的股票。</p>
<h2>机构投资者对 Artivion 的看法</h2>
<p>几家大型投资者最近买入和卖出了该公司的股票。Aster Capital Management DIFC Ltd 在第三季度将其在 Artivion 的持股比例提高了 402.3%。Aster Capital Management DIFC Ltd 目前拥有 648 股公司股票，价值 27,000 美元，此前在上个季度购买了 519 股。Caitong International Asset Management Co. Ltd 在第三季度购买了 Artivion 的新股份，价值约为 27,000 美元。Smartleaf Asset Management LLC 在第二季度将其在 Artivion 的持股比例提高了 47.7%。Smartleaf Asset Management LLC 目前拥有 1,667 股公司股票，估值为 52,000 美元，此前在此期间又收购了 538 股。怀俄明州购买了 Artivion 的新股份，价值约为 80,000 美元。最后，Quadrant Capital Group LLC 在第三季度购买了 Artivion 的新股份，价值约为 92,000 美元。机构投资者持有公司 86.37% 的股票。</p>
<h2>Artivion 的价格表现</h2>
<p>Artivion 股票在周一开盘价为 44.27 美元。该公司的 50 日移动平均线为 45.70 美元，200 日移动平均线为 41.11 美元。该公司的债务与股本比率为 0.50，速动比率为 2.88，流动比率为 3.93。该公司的市值为 21 亿美元，市盈率为-184.47，贝塔值为 1.59。Artivion 的 52 周最低价为 21.97 美元，52 周最高价为 48.25 美元。</p>
<p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）最后一次公布财报是在 11 月 6 日星期四。该公司报告本季度每股收益为 0.16 美元，超出分析师共识预期的 0.14 美元，超出幅度为 0.02 美元。该公司本季度的收入为 1.1339 亿美元，而分析师预期为 1.1071 亿美元。Artivion 的股本回报率为 5.98%，净利润率为-2.16%。该公司本季度的收入同比增长了 18.9%。股票研究分析师预测，Artivion 在当前财政年度将发布 0.37 美元的每股收益。</p>
<h2>关于 Artivion</h2>
<p>（获取免费报告）</p>
<p>Artivion, Inc NYSE: AORT 是一家全球医疗技术公司，开发、制造和销售用于心脏和血管手术的可植入组织产品和外科设备。该公司的产品组合包括来自人类和动物组织的生物植入物，如同种移植物和异种移植物，以及合成支架和外科粘合剂。这些产品旨在在主动脉修复、心脏瓣膜手术和血管重建等手术中修复、加固或替换受损的心血管和胸部组织。</p>
<p>该公司最初成立于 1984 年，名为 CryoLife，并于 2022 年初更名为 Artivion，以反映其在心血管创新方面的更广泛使命。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Artivion 更好</li>
<li>巨大的机器人推广正在进行中</li>
<li>请勿删除，立即阅读</li>
<li>免费：可能改变您生活的加密峰会</li>
<li>新的黄金价格目标</li>
<li>家族信托如何帮助保护您的财富</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Artivion 吗？</h2>
<p>在考虑 Artivion 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Artivion 并不在名单上。</p>
<p>虽然 Artivion 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AORT

<p>Artivion, Inc.（纽约证券交易所代码：AORT）获得了九家券商的 “适度买入” 共识评级。分析师给予了一项卖出、一项持有和七项买入评级，平均目标价为 49.11 美元。最近的内部交易包括首席执行官 James P. Mackin 出售 34,210 股，副总裁 Marshall S. Stanton 出售 47,376 股。机构投资者持有该股票的 86.37%。Artivion 报告上个季度每股收益为 0.16 美元，超出预期，收入同比增长 18.9%</p>

<p>Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have earned a consensus recommendation of &#34;Moderate Buy&#34; from the nine brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $49.1143.</p>
<div class="lb-trans"><p>Artivion, Inc.（纽约证券交易所代码：AORT - 获取免费报告）的股票在目前覆盖该股票的九家券商中获得了 “适度买入” 的共识推荐，Marketbeat 报道称。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，七位给予了买入评级。在过去一年中更新了对该股票覆盖的券商中，平均一年目标价为 49.1143 美元。</p>
</div><p>AORT has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Artivion from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Sunday, December 21st. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Artivion in a research report on Wednesday, October 8th. Needham &amp; Company LLC upped their price objective on Artivion from $50.00 to $58.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 7th. Canaccord Genuity Group reissued a &#34;buy&#34; rating and issued a $51.00 target price on shares of Artivion in a research note on Wednesday, December 17th. Finally, JMP Securities boosted their target price on Artivion from $42.00 to $47.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Friday, October 10th.</p>
<div class="lb-trans"><p>AORT 已成为多份研究分析师报告的主题。华尔街禅在 12 月 21 日的研究报告中将 Artivion 的股票评级从 “买入” 上调至 “强力买入”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Artivion 股票的 “卖出（d-）” 评级。Needham &amp; Company LLC 在 11 月 7 日的报告中将 Artivion 的目标价从 50.00 美元上调至 58.00 美元，并给予该股票 “买入” 评级。Canaccord Genuity Group 在 12 月 17 日的研究报告中重新发布了 “买入” 评级，并对 Artivion 股票设定了 51.00 美元的目标价。最后，JMP Securities 在 10 月 10 日的研究报告中将 Artivion 的目标价从 42.00 美元上调至 47.00 美元，并给予该股票 “市场表现优于大盘” 评级。</p>
</div><p><strong>Read Our Latest Research Report on Artivion</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Artivion 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling at Artivion</h2>
<div class="lb-trans"><h2>Artivion 的内部买卖</h2>
</div><p>In other news, CEO James P. Mackin sold 34,210 shares of the firm's stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $45.86, for a total value of $1,568,870.60. Following the transaction, the chief executive officer owned 800,993 shares of the company's stock, valued at approximately $36,733,538.98. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, SVP Marshall S. Stanton sold 47,376 shares of the business's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the sale, the senior vice president directly owned 44,753 shares of the company's stock, valued at approximately $2,015,675.12. This trade represents a 51.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 234,511 shares of company stock valued at $10,612,452. 8.10% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 James P. Mackin 于 11 月 13 日星期四出售了 34,210 股公司的股票。股票以平均价格 45.86 美元出售，总价值为 1,568,870.60 美元。交易后，首席执行官持有 800,993 股公司股票，估值约为 36,733,538.98 美元。此交易代表其持股比例下降了 4.10%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，副总裁 Marshall S. Stanton 于 11 月 21 日星期五出售了 47,376 股公司的股票。该股票以平均价格 45.04 美元出售，总交易额为 2,133,815.04 美元。出售后，副总裁直接持有 44,753 股公司的股票，估值约为 2,015,675.12 美元。此交易代表其持股比例下降了 51.42%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 234,511 股公司股票，价值 10,612,452 美元。公司内部人士目前持有 8.10% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Artivion</h2>
<div class="lb-trans"><h2>机构投资者对 Artivion 的看法</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd boosted its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company's stock worth $27,000 after purchasing an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth about $27,000. Smartleaf Asset Management LLC grew its stake in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after acquiring an additional 538 shares during the period. State of Wyoming bought a new stake in shares of Artivion in the third quarter worth about $80,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Artivion in the third quarter worth about $92,000. Institutional investors own 86.37% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了该公司的股票。Aster Capital Management DIFC Ltd 在第三季度将其在 Artivion 的持股比例提高了 402.3%。Aster Capital Management DIFC Ltd 目前拥有 648 股公司股票，价值 27,000 美元，此前在上个季度购买了 519 股。Caitong International Asset Management Co. Ltd 在第三季度购买了 Artivion 的新股份，价值约为 27,000 美元。Smartleaf Asset Management LLC 在第二季度将其在 Artivion 的持股比例提高了 47.7%。Smartleaf Asset Management LLC 目前拥有 1,667 股公司股票，估值为 52,000 美元，此前在此期间又收购了 538 股。怀俄明州购买了 Artivion 的新股份，价值约为 80,000 美元。最后，Quadrant Capital Group LLC 在第三季度购买了 Artivion 的新股份，价值约为 92,000 美元。机构投资者持有公司 86.37% 的股票。</p>
</div><h2>Artivion Price Performance</h2>
<div class="lb-trans"><h2>Artivion 的价格表现</h2>
</div><p>Artivion stock opened at $44.27 on Monday. The business's fifty day moving average is $45.70 and its two-hundred day moving average is $41.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. The firm has a market cap of $2.10 billion, a P/E ratio of -184.47 and a beta of 1.59. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25.</p>
<div class="lb-trans"><p>Artivion 股票在周一开盘价为 44.27 美元。该公司的 50 日移动平均线为 45.70 美元，200 日移动平均线为 41.11 美元。该公司的债务与股本比率为 0.50，速动比率为 2.88，流动比率为 3.93。该公司的市值为 21 亿美元，市盈率为-184.47，贝塔值为 1.59。Artivion 的 52 周最低价为 21.97 美元，52 周最高价为 48.25 美元。</p>
</div><p>Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The firm's revenue for the quarter was up 18.9% on a year-over-year basis. Equities research analysts forecast that Artivion will post 0.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）最后一次公布财报是在 11 月 6 日星期四。该公司报告本季度每股收益为 0.16 美元，超出分析师共识预期的 0.14 美元，超出幅度为 0.02 美元。该公司本季度的收入为 1.1339 亿美元，而分析师预期为 1.1071 亿美元。Artivion 的股本回报率为 5.98%，净利润率为-2.16%。该公司本季度的收入同比增长了 18.9%。股票研究分析师预测，Artivion 在当前财政年度将发布 0.37 美元的每股收益。</p>
</div><h2>About Artivion</h2>
<div class="lb-trans"><h2>关于 Artivion</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.</p>
<div class="lb-trans"><p>Artivion, Inc NYSE: AORT 是一家全球医疗技术公司，开发、制造和销售用于心脏和血管手术的可植入组织产品和外科设备。该公司的产品组合包括来自人类和动物组织的生物植入物，如同种移植物和异种移植物，以及合成支架和外科粘合剂。这些产品旨在在主动脉修复、心脏瓣膜手术和血管重建等手术中修复、加固或替换受损的心血管和胸部组织。</p>
</div><p>Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.</p>
<div class="lb-trans"><p>该公司最初成立于 1984 年，名为 CryoLife，并于 2022 年初更名为 Artivion，以反映其在心血管创新方面的更广泛使命。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Artivion</li>
<li>Huge robotics rollout underway</li>
<li>Do not delete, read immediately</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>New gold price target</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Artivion 更好</li>
<li>巨大的机器人推广正在进行中</li>
<li>请勿删除，立即阅读</li>
<li>免费：可能改变您生活的加密峰会</li>
<li>新的黄金价格目标</li>
<li>家族信托如何帮助保护您的财富</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=AORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Artivion Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Artivion 吗？</h2>
</div><p>Before you consider Artivion, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Artivion 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Artivion 并不在名单上。</p>
</div><p>While Artivion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Artivion 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Artivion, Inc.（NYSE 代码：AORT）被分析师给予 “适度买入” 的平均评级